Key Pfizer-Sponsored Data Presentations at the American Society of Hematology (ASH) Congress 2019

The embargo on all abstracts listed below will lift on Wednesday, November 6 when they are published online.

Bosutinib:

(1650) Efficacy Of Bosutinib In Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results From The Phase 4 BYOND Study. Smith BD. Saturday, December 7. Session Type: Poster. Presentation Time: 5:30 – 7:30 PM ET. Location: Hall B.

(1639) Cross-Intolerance With Bosutinib After Prior Tyrosine Kinase Inhibitors In Patients With Chronic Phase Chronic Myeloid Leukemia: BYOND Phase 4 Study. Gjertsen BT. Saturday, December 7. Session Type: Poster. Presentation Time: 5:30 – 7:30 PM ET. Location: Hall B.

(2936) Efficacy And Safety Of Bosutinib By Charlson Comorbidity Index In Previously Treated Patients With Chronic Myeloid Leukemia: Results From The Phase 4 BYOND Study. Gambacorti-Passerini C. Sunday, December 8. Session Type: Poster. Presentation Time: 6:00 – 8:00 PM ET. Location: Hall B.

(4159) Phase 2 Study Of Bosutinib In Japanese Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Takahashi N. Monday, December 9. Session Type: Poster. Presentation Time: 6:00 – 8:00 PM ET. Location: Hall B.

(4157) Maintenance Of Health-Related Quality Of Life In The Phase 4 BYOND Study Of Bosutinib For Pretreated Chronic Phase Chronic Myeloid Leukemia. Brümmendorf TH. Monday, December 9. Session Type: Poster. Presentation Time: 6:00 – 8:00 PM ET. Location: Hall B.

Glasdegib:

(177) A Phase 1b Study Of Glasdegib In Combination With Azacitidine In Patients With Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, And Chronic Myelomonocytic Leukemia. Sekeres MA. Saturday, December 7. Session Type: Oral. Presentation Time: 12:30 PM ET. Location: Chapin Theater.


(3498) Treatment Decision Making In AML: Factors Of Importance To Clinicians, AML Patients And Their Families. LeBlanc TW. Sunday, December 8. Session Type: Poster. Presentation Time: 6:00 – 8:00 PM ET. Location: Hall B.

(3916) Clinical Benefit Of Glasdegib In Combination With Azacitidine Or Low-Dose Cytarabine In Patients With Acute Myeloid Leukemia. Zeidan AM. Monday, December 9. Session Type: Poster. Presentation Time: 6:00 – 8:00 PM ET. Location: Hall B.
Inotuzumab:

(1344) Efficacy And Safety Outcomes In The Phase 3 Ino-Vate Trial By Baseline CD22 Positivity Assessed By Local Laboratories. Kantarjian HM. Saturday, December 7. Session Type: Poster. Presentation Time: 5:30 – 7:30 PM ET. Location: Hall B.

(3427) Estimating The Relative Treatment Effect And Corresponding Cost-Effectiveness Estimates Of Inotuzumab Ozogamicin Vs. Blinatumomab For Adults With Philadelphia Chromosome-Negative (Ph-) Relapsed/Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (B-ALL) In The United Kingdom (UK). Critchlow S. Sunday, December 8. Session Type: Poster. Presentation Time: 6:00 – 8:00 PM ET. Location: Hall B.

PF-06863135 (BCMA):

(1869) Safety, Clinical Activity, Pharmacokinetics, And Pharmacodynamics From A Phase I Study Of PF-06863135, A B-Cell Maturation Antigen (BCMA)–CD3 Bispecific Antibody, In Patients With Relapsed/Refractory Multiple Myeloma (RRMM). Raje NS. Saturday, December 7. Session Type: Poster. Presentation Time: 5:30 – 7:30 PM ET. Location: Hall B.

General Acute Myeloid Leukemia:

(1323) Comparative Analysis Of Patterns Of Infectious Complications Of Outpatient Vs Inpatient Care Following Intensive Induction Chemotherapy For Adults With Acute Myeloid Leukemia (AML) Or Other High-Grade Myeloid Neoplasms. Halpern AB. Saturday, December 7. Session Type: Poster. Presentation Time: 5:30 – 7:30 PM ET. Location: Hall B.

(1317) Comparison Of Outcomes After Early Hospital Discharge (EHD) Following Intensive Induction Vs Post-Remission Chemotherapy For Adults With Acute Myeloid Leukemia (AML) And Other High-Grade Myeloid Neoplasms. Halpern AB. Saturday, December 7. Session Type: Poster. Presentation Time: 5:30 – 7:30 PM ET. Location: Hall B.

###